Why carry out this study?

Although efgartigimod and ravulizumab are both approved for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG), they have not been compared in a head-to-head study.

To address this gap, this study conducted an indirect treatment comparison assessing the relative efficacy of efgartigimod versus ravulizumab in adults with AChR-Ab+ gMG.

What was learned from the study?

Efgartigimod was associated with a statistically significant improvement compared with ravulizumab in terms of Myasthenia Gravis Quality of Life 15-item-revised scale (MG-QoL15r).

Findings were mixed for Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG), with efgartigimod showing a significant improvement over ravulizumab at week 4 and at time of best response, but not over 26 weeks.

The results suggest that efgartigimod provides a faster and greater improvement over 26 weeks in quality of life than ravulizumab in adults with AChR-Ab+ gMG.